The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Gilteritinib and CAR T-cell therapy in high-risk pediatric leukemias
Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, discusses strategies to treat pediatric FLT3-mutant acute myeloid leukemia (AML) and KMT2A-rearranged acute lymphoblastic leukemia (ALL). Pre-clinical studies investigating gilteritinib, a FLT3 inhibitor, have demonstrated that combining gilteritinib and chimeric antigen receptor (CAR) T-cell therapy was effective in the aforementioned patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
